FogPharma

Fog Pharma

Biotechnology, 30 Acorn Park Dr, Cambridge, Massachusetts, 02140, United States, 51-200 Employees

fogpharma.com

  • LinkedIn

phone no Phone Number: 61********

Who is FOGPHARMA

FogPharma is developing a new class of drugs to address the limitations of todays precision medicines and achieve universal druggability. The company is pioneering the discovery, developm...

Read More

map
  • 30 Acorn Park Dr, Cambridge, Massachusetts, 02140, United States Headquarters: 30 Acorn Park Dr, Cambridge, Massachusetts, 02140, United States
  • 2016 Date Founded: 2016
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 32 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from FOGPHARMA

FogPharma Org Chart and Mapping

Employees

Keith Orford

Chief Medical Officer, EVP Clinical, Translational Science

Jesper Andersson

Associate Scientist II, Exploratory Chemistry

Charles Ponthier

Cell Biology Sr. Research Associate

Paul Reitchel

Principal Cloud Engineer

John Cassidy

Director, Information Technology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding FogPharma

Answer: FogPharma's headquarters are located at 30 Acorn Park Dr, Cambridge, Massachusetts, 02140, United States

Answer: FogPharma's phone number is 61********

Answer: FogPharma's official website is https://fogpharma.com

Answer: FogPharma's revenue is $1 Million to $5 Million

Answer: FogPharma's SIC: 2834

Answer: FogPharma's NAICS: 32

Answer: FogPharma has 51-200 employees

Answer: FogPharma is in Biotechnology

Answer: FogPharma contact info: Phone number: 61******** Website: https://fogpharma.com

Answer: FogPharma is developing a new class of drugs to address the limitations of todays precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access